A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Conditions: Niemann-Pick Diseases; Acid Sphingomyelinase Deficiency Interventions: Drug: Olipudase alfa Sponsors: Sanofi; Pulse Infoframe Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials